COVID-19 Therapeutic Options Under Investigation
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
Abstract
Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19–associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients. © Copyright © 2020 Kaddoura, AlIbrahim, Hijazi, Soudani, Audi, Alkalamouni, Haddad, Eid and Zaraket.
Description
Keywords
Adjunctive therapy, Antivirals, Covid-19, Sars-cov-2, Therapeutics, Azithromycin, Bevacizumab, Camostat, Chloroquine, Colchicine, Dexamethasone, Eied 2801, Famotidine, Favipiravir, Fingolimod, Hydroxychloroquine, Ivermectin, Lopinavir plus ritonavir, Methylprednisolone, Nafamstat, Nitazoxanide, Oseltamivir, Penciclovir, Remdesivir, Riamilovir, Ribavirin, Sofosbuvir, Teicoplanin, Thymosin alpha1, Tocilizumab, Umifenovir, Coronavirus disease 2019, Diarrhea, Disease burden, Drug efficacy, Drug repositioning, Drug safety, Gastrointestinal symptom, Human, Mortality rate, Nonhuman, Pandemic, Review, Severe acute respiratory syndrome coronavirus 2, Side effect, Unspecified side effect